Belimumab was recently shown to reduce disease activity in patients with systemic lupus erythematosus. This observation raises important questions about where belimumab might best fit into the ...

In a phase II study, anti-BAFF therapy with belimumab was well-tolerated and had clear effects on B cells. 9 In a detailed analysis of peripheral blood B-cell subsets, belimumab induced dramatic ...

Should Belimumab Have Been Approved? Belimumab was recently approved by the FDA to treat lupus in combination with standard therapies. Dr. Stephen Paget discusses when this drug might come in ...

Further information This topic is currently suspended. Based on the information that is currently available, decision makers have agreed that the subject technology would be appropriate for ...